PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Kalydeco

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. What diagnosis is this drug being prescribed for?

☐ Cystic Fibrosis ☐ Other (Please Specify)

Q2. Please provide ICD code(s) for diagnosis

Q3. Please provide most recent chart note, labs, genotype testing, and any other clinical information that may be useful for the pharmacist and medical director reviewing the request. Coverage will not be approved without documentation to confirm all criteria are met.

Q4. Is patient a NEW START to therapy?

☐ Yes ☐ No - provide start date

Q5. Does the patient have a mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data?

☐ Yes ☐ No

Q6. Does the patient have an AST/ALT < 5 x ULN at baseline, every 3 months of first year, or annually?

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Kalydeco

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

☐ Yes ☐ No

Q7. If the patient is less than18 years of age, has patient had a baseline and, if applicable, follow up ophthalmic exam(s) to check for lens opacities and cataracts?

☐ Yes
☐ No
☐ N/A (Patient >18 years)

Q8. Will the patient be taking any of the following medications along with Kalydeco? (Select all that apply)

☐ Orkambi
☐ Symdeko
☐ Strong CYP3A4 inducers (e.g. barbiturates, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's Wort)
☐ None of the Above

Q9. If request is for CONTINUATION of therapy, is patient's FEV1 stable or has it improved since initiation of therapy?

☐ Yes ☐ No

Q10. If request is for CONTINUATION of therapy, does patient have a documented clinical improvement since initiation of therapy?

☐ Yes ☐ No

Q11. Additional Comments

______________________________ ____________________

Prescriber Signature Date

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Kalydeco

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document